Chemoembolization As Adjuvant Therapy In Hepatocellular Carcinoma

Hepatocellular carcinoma is one of the most common malignancies world wide with an annual occurrence of at least one million new cases.These cases were classified into four groups:First group: Patients included 8 cases. The aim was to study the effect of chemoembolization as neoadjuvant treatment aiming to downstage the tumour size followed by hepatic resection.Second group: Patients included 26 cases. The aim was the study of effect of transarterial chemoembolization as a palliative treatment in management of irresectable hepatocellular carcinoma.Third group: Patients included 20 cases. The aim is to determine the effect of chemoembolization in treatment of recurrent hepatocellular carcinoma.Fourth group: Patients included 12 cases. The aim was to detect the effect of combined transarterial chemoembolization and radiofrequency ablation in managing hepatocellular carcinoma.Most patient in group A had complicationsTACE is a good option for irresectable HCCTACE-RF is used in small HCC